October news roundup
This month’s top news stories.
Severe COVID-19 rare in infants
In a recent study, severe COVID-19 made up 8% of cases among neonates aged less than 28 days.
Case of inflammatory acne or something else?
This case study analyzes variants of majocchi granuloma and potential treatment.
Risk of Cronobacter infection in powdered infant formula
The US Food and Drug Administration recently outlined the risks and symptoms of Cronobacter infection in young infants, and how to reduce risk of infection.
Apremilast may significantly, safely benefit severe pediatric psoriasis
New 16-week data from the SPROUT trial show the PDE4 inhibitor may be highly efficacious in children and adolescents.
Supporting parents of youth with eating disorders in and out of the hospital
At the 2022 AAP National Conference & Exhibition, a practitioner shares her expertise on how to communicate with families to manage a child’s eating disorder (ED) and review practical strategies while increasing patient and family satisfaction.
AAP reports on which children are at greatest risk for COVID-19
At the 2022 American Academy of Pediatrics National Conference & Exhibition, research was presented on which children are at high risk of severe COVID-19.
What is the latest news in COVID-19 vaccines?
As COVID-19 continues to spread, vaccinations remain available to protect children from severe disease, hospitalization, and death.
Poverty increases risk of COVID-19 hospitalization in children
In a recent study, investigators found that children from socioeconomically depraved families were more likely to be hospitalized from COVID-19.
Skin eruptions on infants: self-resolving or concerning?
At the 2022 AAP National Conference & Exhibition, a presenter delves into diagnosis and management of common and uncommon skin rashes in newborns.
Sleep quality improvement in children treated with dupilumab for atopic dermatitis
New research suggests the sleep quality of caregivers and patients with atopic dermatitis (inadequately-controlled with topical therapies) may improve with dupilumab treatment.
